Camrelizumab - CAS 1798286-48-2

Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1/PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.

PD-1/PD-L1

Cell Cycle/Checkpoint, Apoptosis, Immunology/Inflammation

1798236

0.986

-20°C

Ice Packs

Inhibitory Antibodies